Welcome to our dedicated page for Accuray Incorp news (Ticker: ARAY), a resource for investors and traders seeking the latest updates and insights on Accuray Incorp stock.
Accuray Incorporated develops, sells, and supports radiation therapy systems used in cancer treatment and neuro-radiosurgery. Company news centers on product and service revenue, installation timing, gross margin factors, and non-GAAP operating measures, as well as updates tied to its CyberKnife and Radixact treatment platforms and the Accuray Stellar configuration.
Recurring developments also include commercial leadership changes, equity inducement awards, and strategic transformation actions involving organizational realignment, cost structure, outsourcing, engineering resources, and sales enablement. Accuray's updates frame the company as a medical technology issuer with capital equipment sales, service revenue, and global commercialization priorities.
Accuray Incorporated (NASDAQ: ARAY) has announced a significant milestone with the University Hospital Città della Salute e della Scienza in Turin, Italy, successfully treating the first cancer patients in the EIMEA region using the Radixact® System featuring Synchrony® technology. This innovative approach allows for personalized cancer care by adapting treatment based on real-time patient movements, enhancing the precision of radiation therapy. The first patient treated was an 85-year-old man with early-stage lung cancer, benefiting from the system's ability to minimize harm to healthy tissues.
Accuray reported its Q4 and fiscal year 2020 results, highlighting gross orders of $94.3 million and a net revenue of $95.0 million. The company experienced a net loss of $0.8 million for Q4, while fiscal year net income reached $3.2 million. Notably, gross product orders increased by 10% to $377.3 million year-over-year, with an ending backlog of $602.7 million, up 22%. However, the company refrained from providing guidance for fiscal 2021 due to uncertainties surrounding COVID-19.
Accuray Incorporated (NASDAQ: ARAY) announced the appointment of Anne B. Le Grand to its Board of Directors, effective July 16, 2020. Ms. Le Grand brings over 25 years of experience in the healthcare technology sector, previously serving at IBM Watson Health Imaging and Philips Health Systems. Her role aims to enhance Accuray's product innovation in radiation therapy. CEO Joshua H. Levine highlighted her track record in launching market-driven products vital for financial growth. This strategic addition to the board reflects Accuray's commitment to improving cancer treatment.
Accuray Incorporated (NASDAQ: ARAY) will announce its financial results for Q4 and fiscal year 2020, ending June 30, on August 13, 2020. The announcement will take place after market close, followed by a conference call at 1:30 p.m. PT/4:30 p.m. ET. Investors can access a live webcast and a replay on the company’s website. Accuray develops advanced radiotherapy systems aimed at improving cancer treatment outcomes.
Accuray Incorporated (NASDAQ: ARAY) launched the CyberKnife S7 System on June 17, 2020, a robotic, non-invasive radiation therapy device designed for faster and more accurate treatment of tumors. This innovative system integrates real-time AI-driven motion tracking, allowing for treatments to be delivered in as little as 15 minutes. Geisinger Cancer Institute is the first center globally to utilize this technology, enhancing patient care by adapting to patient movement. Moreover, changes in Medicare & Medicaid favor hypofractionated radiotherapy, positioning CyberKnife as a valuable tool for hospitals aiming for clinical effectiveness and return on investment.